Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel
Por:
Pasculli, B, Barbano, R, Rendina, M, Fontana, A, Copetti, M, Mazza, T, Valori, VM, Morritti, M, Maiello, E, Graziano, P, Murgo, R, Fazio, VM, Esteller, M and Parrella, P
Publicada:
17 oct 2019
Categoría:
Multidisciplinary
Resumen:
MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). An association between higher levels of miR-210-3p and risk of disease progression (HR: 2.13, 95%CI: 1.33-3.39, P= 0.002) was found in the subgroup of patients treated with Epirubicin and Cyclophosphamide followed by Docetaxel. Moreover, a cut off value of 20.966 established by ROC curve analyses allowed to discriminate patients who developed distant metastases with an accuracy of 85% at 3- (AUC: 0.870, 95%CI: 0.690-1.000) and 83% at 5-years follow up (AUC: 0.832, 95%CI: 0.656-1.000). Whereas the accuracy in discriminating patients who died for the disease was of 79.6% at both 5- (AUC: 0.804, 95%CI: 0.517-1.000) and 10-years (AUC: 0.804. 95%CI: 0.517-1.000) follow-up. In silico analysis of miR-210-3p and Docetaxel targets provided evidence for a putative molecular cross-talk involving microtubule regulation, drug efflux metabolism and oxidative stress response. Overall, our data point to the miR210-3p involvement in the response to therapeutic regimens including Docetaxel in sequential therapy with anthracyclines, suggesting it may represent a predictive biomarker in breast cancer patients.
Filiaciones:
Pasculli, B:
Fdn IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
Barbano, R:
Fdn IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
Rendina, M:
Fdn IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
Fontana, A:
Fdn IRCCS Casa Sollievo Sofferenza, UO Biostat, San Giovanni Rotondo, FG, Italy
Copetti, M:
Fdn IRCCS Casa Sollievo Sofferenza, UO Biostat, San Giovanni Rotondo, FG, Italy
Mazza, T:
Fdn IRCCS Casa Sollievo Sofferenza, Bioinformat Unit, San Giovanni Rotondo, FG, Italy
Valori, VM:
Fdn IRCCS Casa Sollievo Sofferenza, UO Oncol, San Giovanni Rotondo, FG, Italy
Morritti, M:
Fdn IRCCS Casa Sollievo Sofferenza, UO Oncol, San Giovanni Rotondo, FG, Italy
Maiello, E:
Fdn IRCCS Casa Sollievo Sofferenza, UO Oncol, San Giovanni Rotondo, FG, Italy
Graziano, P:
Fdn IRCCS Casa Sollievo Sofferenza, UO Anat Patol, San Giovanni Rotondo, FG, Italy
Murgo, R:
Fdn IRCCS Casa Sollievo Sofferenza, UO Chirurg Senol, San Giovanni Rotondo, FG, Italy
Fazio, VM:
Fdn IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
:
Bellvitge Biomed Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Catalonia, Spain
Univ Barcelona, Physiol Sci Dept, Sch Med & Hlth Sci, Barcelona, Catalonia, Spain
ICREA, Barcelona, Catalonia, Spain
Parrella, P:
Fdn IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
Green Published, gold
|